- Featured Product
- KD/KO Validated
PD-1/CD279 Polyclonal antibody
PD-1/CD279 Polyclonal Antibody for IHC, IF-P, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
IHC, IF-P, IP, CoIP, ELISA
Conjugate
Unconjugated
Cat no : 18106-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive IHC detected in | human tonsillitis tissue, human lymphoma tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Positive IF-P detected in | human tonsillitis tissue |
Recommended dilution
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
KD/KO | See 2 publications below |
IHC | See 39 publications below |
IF | See 18 publications below |
IP | See 1 publications below |
FC | See 2 publications below |
CoIP | See 1 publications below |
Product Information
18106-1-AP targets PD-1/CD279 in IHC, IF-P, IP, CoIP, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | PD-1/CD279 fusion protein Ag12470 相同性解析による交差性が予測される生物種 |
Full Name | programmed cell death 1 |
Calculated molecular weight | 288 aa, 32 kDa |
GenBank accession number | BC074740 |
Gene symbol | PD-1 |
Gene ID (NCBI) | 5133 |
RRID | AB_10732952 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Programmed cell death 1 (PD-1, also known as CD279) is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 subfamily of the Ig superfamily. It is a 288 amino acid (aa) type I transmembrane protein composed of one Ig superfamily domain, a stalk, a transmembrane domain, and an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based switch motif (ITSM) (PMID: 18173375). PD-1 is expressed during thymic development and is induced in a variety of hematopoietic cells in the periphery by antigen receptor signaling and cytokines (PMID: 20636820). Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function (PMID: 19426218). It is critical for the regulation of T cell function during immunity and tolerance. Blockade of PD-1 can overcome immune resistance and also has been shown to have antitumor activity (PMID: 22658127; 23169436). It has been reported that PD-1 is heavily glycosylated and migrates with an apparent molecular mass of 47-55 kDa on SDS-PAGE , which is larger than its predicted mass of 32 kDa (PMID: 8671665; 17640856; 17003438).
Protocols
Product Specific Protocols | |
---|---|
IHC protocol for PD-1/CD279 antibody 18106-1-AP | Download protocol |
IF protocol for PD-1/CD279 antibody 18106-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Nat Commun ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy | ||
Sci Adv Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions. | ||
J Immunother Cancer Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma. | ||
Mol Ther PD-1/PD-L1 blockade is a potent adjuvant in treatment of Staphylococcus aureus osteomyelitis in mice | ||
Brief Bioinform Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma | ||